Akero Therapeutics Reports Exciting Results from SYMMETRY Study
SOUTH SAN FRANCISCO, Calif. — Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biopharmaceutical company, is making strides in treating serious metabolic conditions like compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis, commonly referred to as MASH. The recent unveiling of their Phase 2b SYMMETRY study results has provided significant insights into the effectiveness of their leading drug candidate, efruxifermin (EFX).
Significant Improvements in Patients’ Condition
As part of the SYMMETRY study, the company evaluated the efficacy and safety of EFX in patients diagnosed with biopsy-confirmed compensated cirrhosis (F4). Among patients with initial and week 96 biopsies, a remarkable 39% of those receiving a 50mg dose of EFX showed at least a one-stage improvement in fibrosis without any worsening of MASH. This result reflects a substantial effect size of 24% when compared to a mere 15% observed in the placebo group.
ITT Analysis Shows Positive Outcomes
In an intent-to-treat (ITT) analysis, which included patients irrespective of their follow-up biopsy results, 29% of those assigned to the 50mg EFX group experienced significant improvements. This indicated an effect size of 17% over the placebo, which evidenced only a 12% improvement.
Long-term Benefits of EFX Treatment
The study indicated that extending the treatment duration from 36 weeks to 96 weeks resulted in more than doubled effectiveness in the EFX group. This reinforced the notion that consistent treatment with EFX can substantially benefit patients suffering from compensated cirrhosis due to MASH.
Subgroup Analysis Highlights Non-GLP-1 Users
A subgroup analysis targeting patients not treated with GLP-1 therapy revealed even more promising results. In this cohort, a striking 45% of patients treated with 50mg EFX exhibited improvements, versus just 17% in the placebo group. This suggested that EFX's efficacy is independent of concurrent GLP-1 therapy, adding to the credibility of its transformative potential.
Expert Opinions on the SYMMETRY Results
Experts in the field have expressed optimism regarding the findings. Dr. Mazen Nourredin, a Professor of Medicine and Principal Investigator of the study, remarked on the historical lack of effective treatments for compensated cirrhosis due to MASH, emphasizing the newfound hope provided by EFX.
Encouraging Path Forward
Andrew Cheng, President and CEO of Akero, reinforced this sentiment, highlighting the study's results as groundbreaking. The proven capability of EFX, illustrated by both completer and ITT analyses, distinguishes it from existing treatments and emphasizes its potential to positively impact patients' lives significantly.
Understanding Cirrhosis and MASH
Cirrhosis related to MASH is recognized as a serious health issue, associated with heightened risks of liver failure, cancer, and a substantial decrease in life expectancy. Data suggests that by the end of this decade, millions are expected to suffer from MASH cirrhosis, further stressing the urgent need for effective interventions.
Details on the SYMMETRY Study
The SYMMETRY study encompassed a broad range of participants, looking at various dosing regimens of EFX against placebo over extensive periods. The primary aim was to determine the proportion of patients who achieved fibrosis improvement without a decline in MASH status. Secondary measures evaluated included liver enzyme levels, non-invasive fibrosis markers, and overall safety.
Ongoing Studies and Future Directions
Currently, Akero is advancing EFX through three pivotal Phase 3 clinical trials, which evaluate its benefits across different population segments affected by MASH. The ongoing studies emphasize Akero's commitment to addressing this demanding area of medical need with innovative solutions.
Potential and Tolerability of EFX
EFX has been observed as generally well-tolerated among patients, with minimal serious adverse events reported. The most common side effects included gastrointestinal issues, underscoring its potential for a favorable safety profile for long-term use.
Frequently Asked Questions
What is efruxifermin (EFX)?
Efruxifermin (EFX) is Akero's lead investigational drug aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) and its complications, including compensated cirrhosis.
How effective is EFX based on the SYMMETRY study results?
The SYMMETRY study displayed that 39% of patients receiving 50mg of EFX experienced at least one stage improvement in fibrosis after 96 weeks, showcasing significant efficacy for patients with compensated cirrhosis.
Are there any safety concerns with EFX?
Overall, EFX has shown a good safety profile without reported deaths related to the treatment, though some gastrointestinal adverse effects were noted.
What are the next steps for Akero Therapeutics?
Akero plans to continue evaluating EFX's effectiveness in ongoing Phase 3 studies to further establish its role in treating MASH-related conditions.
Why is the SYMMETRY study important?
The SYMMETRY study is pivotal as it is the first to demonstrate reversal of compensated cirrhosis due to MASH, positioning EFX as a potentially groundbreaking treatment in this challenging therapeutic space.
